Newsbenzinga
Amgen, AstraZeneca Drug Combo Shows Promising Survival Results in Tough-To-Treat Lung Cancer
· Published
Article summary
Amgen's Imdelltra with Imfinzi cut small-cell lung cancer death risk by 58% in Phase 3, extending median survival to 21.1 months. Read more.
An excerpt from the original article.
Comments —
Loading comments…